Agilon Health, Inc.
AGL · NYSE
Analyst ratings
buy · 9 ratings
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| July 13, 2026 | Wells Fargo | Maintains | Overweight | $141.00 |
| May 21, 2026 | Benchmark | Maintains | Buy | $95.00 |
| May 15, 2026 | Citigroup | Maintains | Neutral | $80.00 |
| May 11, 2026 | TD Cowen | Maintains | Hold | $55.00 |
| May 8, 2026 | Wells Fargo | Maintains | Overweight | $72.00 |
| May 7, 2026 | Evercore ISI Group | Maintains | In-Line | $32.00 |
| May 7, 2026 | Jefferies | Upgrades | Buy | $48.00 |
| May 7, 2026 | Baird | Maintains | Neutral | $35.00 |
| May 7, 2026 | Deutsche Bank | Upgrades | Buy | $49.00 |
| April 2, 2026 | Benchmark | Maintains | Buy | $13.00 |
| March 3, 2026 | Citigroup | Maintains | Neutral | $18.75 |
| February 27, 2026 | Wells Fargo | Maintains | Overweight | $37.50 |
| February 27, 2026 | Barclays | Maintains | Underweight | $12.50 |
| November 6, 2025 | Barclays | Maintains | Underweight | $25.00 |
| November 5, 2025 | Wells Fargo | Maintains | Overweight | $25.00 |
| October 7, 2025 | Wells Fargo | Maintains | Overweight | $37.50 |
Path to profitability and sustainability of earnings improvement
Agilon Health delivered a dramatic Q1 2026 EPS of $1.80–$2.94, vastly exceeding forecasts, driven by favorable medical expense management and improved Medicare Advantage results. Adjusted EBITDA surged to $54 million versus $21 million a year prior, signaling a credible inflection toward profitability by 2028.
Despite the earnings beat, the company still posts negative full-year EPS (consensus at -$3.5 for the current year), and JPMorgan downgraded shares to 'underweight,' reflecting skepticism that recent outperformance is sustainable rather than a one-time benefit from temporarily low medical cost trends.
Stock valuation and appropriate price target range
Deutsche Bank and Jefferies both upgraded Agilon Health to 'buy' and raised price targets, while InvestingPro's Fair Value assessment suggests the stock remains undervalued even near its 52-week high. Bernstein SocGen raised its target to $86 and Leerink to $92, citing improved fundamentals.
Analyst consensus remains a 'Hold' with an average target of $58–$64, well below recent trading prices above $120. Citigroup maintained a 'neutral' rating, Truist reiterated 'Hold' at $67, and technical indicators flag the stock trading in overbought territory near its 52-week high.
Long-term viability of the Medicare Advantage-dependent business model
Agilon Health's strong Q1 2026 performance, including revenue of $1.42 billion beating estimates, reflects growing investor confidence in its value-based care model. The company's expanding footprint in the healthcare sector and improving cost management suggest the Medicare Advantage partnership model is gaining traction.
Weiss Ratings cut Agilon Health deeper into 'sell' territory, and earlier technical analysis pointed to sustained downward price momentum and a lack of positive signals. The business remains heavily exposed to Medicare Advantage reimbursement dynamics, making earnings inherently volatile and difficult to forecast consistently.